What is TG Therapeutics Inc?
, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 9.75B, and a P/E ratio of 96.3x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.